Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL10180078 | 0.83 | TSHR (0.40) | — | |
| Tetramethylammonium Ion SCHEMBL10181375 | 0.82 | — | — | |
| SCHEMBL8781561 | 0.79 | BBOX1 (0.34) | BBOX1 | |
| SCHEMBL19348687 | 0.79 | BBOX1 (0.34) | BBOX1 | |
| Phosphoric Acid SCHEMBL4405667 | 0.79 | BBOX1 (0.42) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL10788757 | 0.78 | LMNA (0.33) | LMNAESR1ADORA3CDC25AAGTR1 | |
| Diethyl Hydrogen Phosphate SCHEMBL19712620 | 0.76 | TSHR (0.42) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL28715633 | 0.76 | FAAH (0.34) | BBOX1 | |
| SCHEMBL19348699 | 0.75 | BBOX1 (0.32) | BBOX1 | |
| Phosphoric Acid SCHEMBL31122134 | 0.74 | BBOX1 (0.50) | BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222624-B1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO LTD (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CENTRAL GLASS CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| EP-3222624-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | Central Glass Co., Ltd. (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO., LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CA2, CA6, CHRM1 | LMNA 4080/4885ESR1 1159/4885ADORA3 163/4885 |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CA2, CA6, CHRM1 | LMNA 4080/4885ESR1 1159/4885ADORA3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.